Swedish Orphan Biovitrum (Sobi) is to appeal against the European Medicines Agency’s decision that its drug Gamifant (emapalumab) should not be approved for use across the EU for the treatment of primary hemophagocytic lymphohistiocytosis (HLH).
Gamifant was one of two drugs that the EMA this week recommended should not be approved. The other is Elzonris...








